Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics

Josée Golay, Gianpietro Semenzato, Alessandro Rambaldi, Robin Foà, Gianluca Gaidano, Enrica Gamba, Fabrizio Pane, Antonello Pinto, Giorgina Specchia, Francesco Zaja, Mario Regazzi

Research output: Contribution to journalArticlepeer-review


The anti-CD20 antibody rituximab (RTX; Rituxan®, MabThera®) was the first anti-cancer antibody approved by the US Food and Drug Administration in 1997 and it is now the most-studied unconjugated therapeutic antibody. The knowledge gained over the past 15 y on the pharmacodynamics (PD) of this antibody has led to the development of a new generation of anti-CD20 antibodies with enhanced efficacy in vitro. Studies on the pharmacokinetics (PK) properties and the effect of factors such as tumor load and localization, antibody concentration in the circulation and gender on both PK and clinical response has allowed the design of optimized schedules and novel routes of RTX administration. Although clinical results using newer anti-CD20 antibodies, such as ofatumumab and obinutuzumab, and novel administration schedules for RTX are still being evaluated, the knowledge gained so far on RTX PK and PD should also be relevant for other unconjugated monoclonal antibody therapeutics, and will be critically reviewed here.

Original languageEnglish
Pages (from-to)826-837
Number of pages12
Issue number6
Publication statusPublished - 2013


  • B-NHL
  • CLL
  • FcRn
  • FcγRs
  • Pharmacodynamics
  • Pharmacokinetics
  • Rituximab

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Medicine(all)


Dive into the research topics of 'Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics'. Together they form a unique fingerprint.

Cite this